A 'Must Read' for Breast Cancer Patients
Patent 7,309,486 discloses novel protocols that allow the two classes ofchemotherapeutics to function synergistically. The protocols are designed toprovide a way of holding the cancer in check indefinitely.
All proliferating cells progress through 4 distinct phases termed G1, S,G2, and M. "S-Phase cytotoxics, such as Pfizer's Camptosar(R) or Eli Lilly'sGemzar(R), are capable of killing virtually all cells that are in the S-Phase,however, in the best case, only around one third of cancer cells are typicallyin the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor."The patented protocols boost the number of cells in the S-Phase by exploitingthe cancer's unique mutation profile to establish a "road block" to aggregatea large number of cancer cells at a point prior to the S-Phase, the road blockis then removed to allow the wave of cancer cells to enter the S-Phase duringthe administration time of the S-Phase cytotoxic chemotherapy, and then theroad block is reestablished to start aggregating surviving cancer cells forthe next administration of S-Phase cytotoxic chemotherapy."
The abstract contained in the patent has been incorrectly truncated and acorrect synopsis of the patent is available at http://www.nexgen.biz underCell Cycle Synchronous Chemotherapy.
SOURCE NexGen Biomedical, Inc.
You May Also Like